Mutant anaplastic lymphoma kinase inhibitor identification by integrated in silico approaches

Abstract

Non-small-cell lung cancer (NSCLC) is the primary form of lung cancer globally and remains a leading cause of mortality. Anaplastic lymphoma kinase (ALK) mutations, such as I1171N + L1198H, have been discovered to confer resistance to current ALK inhibitors, reducing their therapeutic effectiveness. Addressing drug resistance necessitates exploring selective inhibitors for innovative therapeutic approaches. In this study, a structure-based pharmacophore model, using ALK-approved inhibitors, was developed to screen an In-house database for potential mutant ALK inhibitors. Compounds with requisite pharmacophoric features were evaluated for binding potential against the I1171N + L1198H ALK mutant phenotype. Selected hits underwent assessment for chemical reactivity, and dynamics stability. The study identified five chemical scaffolds (NS1-5) with favorable binding modes and pharmacokinetic properties. The conformational ensembles featured the average RMSD values, ranging from 0.4 to 0.6 nm. RMSF analysis revealed consistent side chain fluctuations with reduced flexibility, while Rog analysis indicated convergence of most complexes. NS1 and NS5, in particular emerged as promising candidates, exhibiting remarkable performance than others, with binding free energies of −210.12 ± 9.94 and −163.68 ± 11.14 kcal/mol, respectively. These findings thus suggest further exploration and optimisation of NS1 and NS5 for mutant ALK inhibitors for the treatment of NSCLC.